** Maxim Group cuts PT on drug developer Acrivon Therapeutics ACRV.O to $7 from $24
** Cites deprioritization of ovarian and bladder programs
** "Management announced that due to a higher bar in ovarian cancer and difficulty recruiting OncoSignature positive patients in bladder cancer, the company is deprioritizing these programs," says brokerage
** Adds the data in endometrial cancer is still quite strong and with a positive safety profile
** New PT is ~245% upside to stock's last close
** Nine of 10 brokerages rate stock "buy" or higher, and 1 "hold"; median PT is $15 - data compiled by LSEG
** ACRV shares down ~66% YTD, as of last close; they rose ~22% in 2024
(Reporting by Ateev Bhandari in Bengaluru)
((Ateev.Bhandari@thomsonreuters.com; ))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.